Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics

Dr. Reddy's Laboratories Ltd (RDY)

Today's Latest Price: $44.80 USD

0.05 (-0.11%)

Updated Feb 21 6:30pm

Add RDY to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RDY Stock Summary

  • The price/operating cash flow metric for Dr Reddys Laboratories Ltd is higher than merely 1.69% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of -17.35%, Dr Reddys Laboratories Ltd's debt growth rate surpasses merely 14.85% of about US stocks.
  • Dr Reddys Laboratories Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 285.51%, greater than the shareholder yield of 98.93% of stocks in our set.
  • Stocks that are quantitatively similar to RDY, based on their financial statements, market capitalization, and price volatility, are CYD, WBC, EMN, MOG.A, and ST.
  • Visit RDY's SEC page to see the company's official filings. To visit the company's web site, go to www.drreddys.com.
RDY Daily Price Range
RDY 52-Week Price Range

RDY Stock Price Chart More Charts

RDY Price/Volume Stats

Current price $44.80 52-week high $46.19
Prev. close $44.85 52-week low $34.67
Day low $44.66 Volume 108,071
Day high $45.28 Avg. volume 209,600
50-day MA $42.45 Dividend yield 0.58%
200-day MA $39.16 Market Cap 7.42B

Dr. Reddy's Laboratories Ltd (RDY) Company Bio

Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.

RDY Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$44.80$2170.14 4654%

Below please find a table outlining a discounted cash flow forecast for RDY, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Dr Reddys Laboratories Ltd ranked in the 96st percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 4677.17% on a DCF basis. The most interesting components of our discounted cash flow analysis for Dr Reddys Laboratories Ltd ended up being:

  • The company has produced more trailing twelve month cash flow than 99% of its sector Healthcare.
  • The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than merely 20.79% of the free cash flow producing stocks we're observing.
  • RDY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 48.6% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Dr Reddys Laboratories Ltd? See ASRT, FVE, BEAT, CORT, and USNU.

RDY Latest News Stream

Event/Time News Detail
Loading, please wait...

RDY Latest Social Stream

Loading social stream, please wait...

View Full RDY Social Stream

RDY Price Returns

1-mo 5.21%
3-mo 12.85%
6-mo 27.78%
1-year 25.30%
3-year 4.75%
5-year -15.26%
YTD 10.40%
2019 8.38%
2018 1.18%
2017 -16.47%
2016 -1.67%
2015 -7.76%

RDY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RDY Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6534 seconds.